Medicis Has an Earnings Glow

S&P ranks Medicis Pharmaceutical a strong buy, thanks in part to an expanding dermatological product line, including a new treatment to compete with Botox

Medicis Pharmaceutical (MRX; $27.50) is the largest independent dermatological company in the U.S., focusing primarily on the anti-acne and dermal filler sections of the market. We believe that the company, under the leadership of founder, Chairman, and Chief Executive Jonah Shacknai, has been able to reinvent itself with the development of a new portfolio of popular aesthetic dermatological products such as Solodyn and Ziana acne treatments, and Restylane and Perlane hyaluronic acid-based dermal fillers. These products have more than compensated for dwindling sales of its older, off-patent Dynacin, Plexion, and Triaz lines.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.